Main Menu

Eagle Pharmaceuticals, Inc.

(NASDAQ GM: EGRX)

Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Eagle Pharmaceuticals, Inc. (“Eagle Pharmaceuticals” or the “Company”) (NASDAQ GM: EGRX) on behalf of stockholders.

This investigation covers stockholders who purchased or otherwise acquired Eagle Pharmaceuticals shares on or before August 8, 2023 and who continue to hold their shares.

ABOUT THE INVESTIGATION:

The investigation concerns whether Eagle Pharmaceuticals and certain of its directors and/or officers issued materially misleading information and/or failed to disclose material information to the investing public. Specifically, the investigation concerns whether Eagle Pharmaceuticals and certain of its directors and/or officers failed to disclose to shareholders that: (i) Eagle Pharmaceuticals was experiencing slower-than-anticipated pull-through from a wholesaler customer predominately due to expiry of inventory; (ii) as a result, Eagle Pharmaceuticals overstated its revenue; and (iii) the Company did not have effective internal controls and procedures over financial reporting for the sales of PEMFEXY, one of Eagle Pharmaceuticals’ commercial products.

THERE IS NO COST TO YOU.

There is no cost to you to join this action. We represent investors on a contingency fee basis. This means that we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees only if we are successful.

If you are interested in joining the action or receiving more information, you may fill out the form below or contact Leah Wihtelin cost free at (516) 693-8926 or by email at lw@rl-legal.com.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to info@rl-legal.com.

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 12/30/2024


* Indicates a required field.

Back to Page